Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. Aug. 13, 2018. Jonathan Phillips.

Executive Summary

When it comes to opioids and enforcement, the US Department of Justice is largely focused on the drug side. But Gibson Dunn attorney Jonathan Phillips says that doesn’t mean device-makers should be complacent about opioid enforcement activities. See what he said here.

"The government activity in that space shows how, when it is looking to further a policy interest that it considers particularly important, it can direct the full extent of its enforcement capabilities to bear. It's so broad now: It's civil, it's criminal, it's federal, it's state, it's False Claims Act, it's multi-district litigation, and then they're going over not only the manufacturers, but also pharmacies that are dispensing opioids, physicians who are prescribing opioids, and anyone who might be involved to a significant extent in the distribution of opioids." Jonathan Phillips, attorney, Gibson Dunn

Click here for a free trial of Medtech Insight


Related Content

Mid-Year Enforcement Roundup: Focus On Opioids, As Other Areas Lag





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts